Fig. 4: Single-tumor antigen (TRP2180–188) display by catcher-decorated OMVs.
a Schema showing the B16-F10 melanoma lung metastasis mouse model and the OMVs vaccination (Vacc.) timeline. C57BL/6 mice were inoculated with B16-F10 melanoma cells (n = 4, 2 × 105 cells/mouse, i.v.), then immunized with the following vaccines or controls: saline; SnT-TRP2; CN OMVs; SnT-TRP2 + CN OMVs; or CC-SnT-TRP2 OMVs on days 3, 6, and 11 after inoculation of the tumor cells. Lung metastasis and immune responses were analyzed on day 17. TRP2: tyrosinase-related protein 2. b, c Analysis of DC maturation in inguinal lymph nodes at the end of the treatment period (day 17). The percentage of CD80+ (b) or CD86+ (c) cells in CD11c+ cells was determined by flow cytometry. d, e Lungs were collected at the end of the treatment period and photographed (d), then the tumor nodules in the lung were counted (e). f Flow cytometry analysis of IFNγ+ cytotoxic T lymphocytes in splenocytes re-stimulated with TRP2180-188 antigen. The percentage of IFNγ+ cells in the CD3+CD8+ T-cell subpopulation is shown. g, h IFNγ secretion from splenocytes (as determined by the ELISPOT assay) which had been re-stimulated with TRP2180–188 (g). Quantitative analysis of the ELISPOT data is shown in (h). The data (b, c, e, f, h) are shown as mean ± SD. Statistical analysis was performed by a two-tailed unpaired t test. N.S. no significance. Source data are provided as a Source Data file.
